EX-4.4





 Exhibit 4.4 
  

			
	DATED	  	2020

 CONFORMED COPY 

(1) TIZIANA LIFE SCIENCES PLC 
 (2)
ACCUSTEM SCIENCES PLC 
  
  

SUPPLEMENTAL DEMERGER AGREEMENT - OPTIONS, 

WARRANTS, RIGHTS TO CALL AND FURTHER 

INVESTMENT 
  

 
  





 












 TABLE OF CONTENTS 

 

							
	 	 	 	  	Page	 
	 1.
	 	INTERPRETATION	  	 	1	 
			
	 2.
	 	ACCRUED RIGHTS OF CERTAIN PERSONS	  	 	3	 
			
	 3.
	 	THE PLACING	  	 	4	 
			
	 4.
	 	FURTHER ASSURANCE	  	 	4	 
			
	 5.
	 	ASSIGNMENT	  	 	4	 
			
	 6.
	 	ENTIRE AGREEMENT	  	 	4	 
			
	 7.
	 	VARIATION AND WAIVER	  	 	4	 
			
	 8.
	 	COSTS	  	 	5	 
			
	 9.
	 	NOTICE	  	 	5	 
			
	 10.
	 	SEVERANCE	  	 	6	 
			
	 11.
	 	AGREEMENT SURVIVES THE DEMERGER EFFECTIVE DATE	  	 	6	 
			
	 12.
	 	THIRD PARTY RIGHTS	  	 	6	 
			
	 13.
	 	COUNTERPARTS	  	 	7	 
			
	 14.
	 	GOVERNING LAW AND JURISDICTION	  	 	7	 
		
	 SCHEDULE 1
	  	 	8	 


  
 -i- 













 SUPPLEMENTAL DEMERGER AGREEMENT 

 

			
	DATED	 	2020

 BETWEEN: 
  

	(1)	 TIZIANA LIFE SCIENCES PLC, a company incorporated and registered in England and Wales with company
number 03508592 whose registered office is at 3rd Floor 11-12 St. James’s Square, London SW1Y 4LB (“Topco”); and



  

	(2)	 ACCUSTEM SCIENCES LIMITED, a company incorporated and registered in England and Wales with company
number 12647178 whose registered office is at 9th Floor, 107 Cheapside, London EC2V 6DN (“Newco”). 



BACKGROUND 
  

	(A)	 Topco has announced its intention to effect the Demerger pursuant to which Newco will become the new holding
company for the Demerged Business by virtue of its ownership of the Company and intends to seek admission of the Newco Shares to listing on the Official List and to trading on the Main Market of the London Stock Exchange. 



 

	(B)	 Topco and Newco are party to a Demerger Agreement governing the implementation of the Demerger.



  

	(C)	 The parties wish to record certain additional terms upon which are intended to be encapsulated in the Demerger.



 AGREED TERMS 
  

	1.	 INTERPRETATION 



 

	1.1	 In this agreement, unless the context otherwise requires: 



“Circular” means the circular sent to the Topco Shareholders and incorporating a notice of a general meeting of Topco which
was held on 2 October 2020 in relation to the approval of the Reduction of Capital and the Demerger; 
 “Company” means
StemPrintER Sciences Limited, a company incorporated and registered in England and Wales with company number 12856894 whose registered office is at 9th Floor, 107 Cheapside, London EC2V 6DN; 

“Demerger” means the proposed transfer of the Company Shares by Topco to Newco pursuant to the Reduction of Capital; 

“Demerger Record Time” means 7:00 a.m. on 30 October 2020; 

“Newco IPO” means the admission of all Newco Shares to the standard segment of the official list of the FCA and to trading on
the main market of the London Stock Exchange plc, which is expected to occur in late Q4 2020; 

  
 1 













 “Newco Shares” means the ordinary shares of £0.01 each in the capital
of Newco from time to time; 
 “Placing Price” the price at which newco issues Newco Shares in a placing in connection with
admission of its share capital to trading on the standard segment of the official list of the FCA and to trading on the main market of the London Stock Exchange plc. 

“Reduction of Capital” means the court approved reduction of capital of Topco pursuant to the Companies Act 2006, which became
effective on 29 October 2020, as more particularly described in the Circular; 
 “Topco Shares” means the ordinary
shares of £0.03 each in the capital of Topco from time to time; and 
 “Topco Side Liability” means any Liability,
whenever and howsoever suffered or incurred by any Newco Group Company which is directly or indirectly attributable to the Retained Business or to any of the steps involved in the Demerger being held to be illegal, void or unenforceable but
excluding any Liability which is expressly provided for under this agreement. 
  

	1.2	 In this agreement, unless the context otherwise requires: 



 

	 	(a)	 references to “this agreement” shall include the Background and Schedules to it, which form
part of this agreement, and references to clauses, the Background and Schedules are to clauses of and the Background and Schedules to this agreement; 


  

	 	(b)	 clause, Schedule and paragraph headings shall not affect the interpretation of this agreement;



  

	 	(c)	 references to clauses and Schedules are to the clauses of, and Schedules to, this agreement and references to
paragraphs are to paragraphs of the relevant Schedule; 


  

	 	(d)	 the Schedules form part of this agreement and shall have effect as if set out in full in the body of this
agreement. Any reference to this agreement includes the Schedules; 


  

	 	(e)	 a reference to a “company” shall include any company, corporation or other body corporate,
wherever and however incorporated or established; 


  

	 	(f)	 a reference to a “holding company” or a “subsidiary” means a holding company
or a subsidiary (as the case may be) as defined in section 1159 of the Companies Act 2006; 


  

	 	(g)	 a reference to a statute, statutory provision or subordinate legislation is a reference to it as it is in force
from time to time and includes any statute, statutory provision or subordinate legislation which it amends or re-enacts and subordinate legislation for the time being in force made under it;




  
 2 














	 	(h)	 a reference to “writing” or “written” includes email; 



 

	 	(i)	 any words following the terms “including”, “include”,
“in particular”, “for example” or any similar expression shall be construed as illustrative and shall not limit the sense of the words, description, definition, phrase or term preceding those terms. Where the
context permits, “other” and “otherwise” are illustrative and shall not limit the sense of the words preceding them; and 


  

	 	(j)	 references to a document in “agreed form” are to that document in the form agreed by the
parties or on their behalf and initialled by them or on their behalf for identification. 


  

	2.	 ACCRUED RIGHTS OF CERTAIN PERSONS 



 

	2.1	 The Circular identified that certain holders of options and warrants, the exercise of which would result in the
issue of additional Topco Shares and suggested that appropriate proposals would be extended to such persons. 


  

	2.2	 Newco shall procure that: 



 

	 	(a)	 an additional 4,763,995 Newco Shares are issued to Gabriele Cerrone to reflect a realisation bonus accrued in
Topco and in respect of which Mr Cerrone is unconditionally entitled through the issue of 4,763,995 Topco Shares (but for constraints on timing of delivery under Note 11 to Rule 9 of the UK Takeover Code); 



 

	 	(b)	 an additional 397,347 Newco Shares are issued to Panetta Partners Limited to reflect a convertible loan note
outstanding from Topco and in respect of which Panetta Partners Limited is entitled to exercise its conversion rights to convert the loan note and accrued interest and the exercise of associated warrants into397,347 Topco Shares (but for constraints
on timing of exercise under Note 11 to Rule 9 of the UK Takeover Code); 


  

	 	(c)	 an additional 1,830,775 Accustem Shares to Gabriele Cerrone credited as fully paid in respect of share options
which Gabriele Cerrone would have exercised (and has undertaken to exercise) but for the constraints imposed by Note 11 to Rule 9 of the UK Takeover Code; 


  

	 	(d)	 an additional 2,589,137 Accustem Shares to Gabriele Cerrone credited as fully paid in respect of a convertible
loan note in respect of which Gabriele Cerrone would have exercised underlying conversion rights (and has undertaken to exercise the same) but for the constraints imposed by Note 11 to Rule 9 of the UK Takeover Code; and 



 

	 	(e)	 to the extent that such shares were not entered in the register of members of Tiziana prior to the record date
for the Demerger, the number of Newco Shares listed on the Schedule be issued to the persons listed in the Schedule credited as fully paid to reflect the exercise of certain holdings of options and warrants. 



  
 3 














	2.3	 The allotment and issue by Newco of the Newco Shares pursuant to clause 2.2 (a) to (d) shall be satisfied
by Topco paying to Newco the sum equal to 1.58 pence per NewCo Share, being the aggregate nominal value of the additional Newco Shares and a total payment of £151,383. 



 

	3.	 THE PLACING 



Topco agrees invest the sum of £2,000,000 in Newco Shares at the Placing Price in the Newco IPO. 

 

	4.	 FURTHER ASSURANCE 



At its own expense, each party and each of its subsidiaries shall, and shall use reasonable endeavours to ensure that any necessary third party
shall, promptly execute and deliver such documents and perform such acts as any other party may reasonably require from time to time for the purpose of giving to that other party the full benefit of all the provisions of this agreement. 

 

	5.	 ASSIGNMENT 


  

	5.1	 This agreement is personal to the parties and neither party shall assign, transfer, mortgage, charge, declare a
trust of, or deal in any other manner with any of its rights and obligations under this agreement without the prior written consent of the other party. 


  

	5.2	 Subject to clause 4.1, this agreement shall be binding on and shall enure to the benefit of the parties to this
agreement and their respective successors and permitted assigns. 


  

	6.	 ENTIRE AGREEMENT 



This agreement (together with the documents referred to in it) constitutes the entire agreement between the parties and supersedes and
extinguishes all previous discussions, correspondence, negotiations, drafts, agreements, promises, assurances, warranties, representations and understandings between them, whether written or oral, relating to their subject matter. 

 

	7.	 VARIATION AND WAIVER 



 

	7.1	 No variation of this agreement shall be effective unless it is in writing and signed by the parties (or their
authorised representatives). 


  

	7.2	 A failure or delay by any person to exercise any right or remedy provided under this agreement or by law shall
not constitute a waiver of that or any other right or remedy, nor shall it prevent or restrict the further exercise of that or any other right or remedy. No single or partial exercise of any right or remedy provided under this agreement or by law
shall prevent or restrict the further exercise of that or any other right or remedy. 


  

	7.3	 Except as expressly provided otherwise in this agreement, the rights and remedies provided under this agreement
are in addition to, and not exclusive of, any rights or remedies provided by law. 



  
 4 














	8.	 COSTS 



Except as expressly provided in this agreement, all costs in connection with the negotiation, preparation, execution and performance of this
agreement, and any documents referred to in it, shall be borne by Topco. 
  

	9.	 NOTICE 


  

	9.1	 19.1     A notice given to a party under or in connection with this agreement:



  

	 	(a)	 shall be in writing and in English; 



 

	 	(b)	 shall be sent to the relevant party for the attention of the contact and to the address email address specified
in clause 8.2 (or such other address, email address or person as that party may notify to the other in accordance with the provisions of this clause 8); and 


  

	 	(c)	 shall be: 


  

	 	(i)	 delivered by hand; 


  

	 	(ii)	 sent by email; 


  

	 	(iii)	 sent by pre-paid first-class post or another next working day delivery
service providing proof of delivery; and 


  

	 	(d)	 unless proved otherwise is deemed received as set out in clause 8.4. 



 

	9.2	 The addresses, email addresses, and named contacts for service of notice are: 



 

	 	(a)	 Topco 


  

	 	(i)	 address:             3rd Floor 11-12 St James’s Square 



	 	                                  
  London	 SW1Y 4LB 


  

	 	(ii)	 for the attention of: [REDACTED] 



 

	 	(iii)	 email address: [REDACTED] 



 

	 	(b)	 Newco 


  

	 	(i)	 address:             9th Floor, 107 Cheapside 



	 	                                  
  London	 EC2V 6DN 


  

	 	(ii)	 for the attention of: [REDACTED] 



 

	 	(iii)	 email address: [REDACTED] 



  
 5 














	9.3	 A party may change its details for service of notices as specified in clause 8.2 by giving notice to the other
party, provided that in the case of change to the party’s postal address the new address is an address in the UK. Any change notified pursuant to this clause shall take effect at 9.00 a.m. on the later of: 



 

	 	(a)	 the date (if any) specified in the notice as the effective date for the change; and 



 

	 	(b)	 five Business Days after deemed receipt of the notice of change. 



 

	9.4	 Delivery of a notice is deemed to have taken effect (provided that all other requirements in this clause have
been satisfied): 


  

	 	(a)	 if delivered by hand, on signature of a delivery receipt or at the time the notice is left at the address;



  

	 	(b)	 if sent by email, at the time of transmission; 



 

	 	(c)	 in the case of pre-paid first-class post or another next working day
delivery service delivery to an address in the UK, at 9.00 am on the second Business Day after posting or at the time recorded by the delivery service; 


  

	 	(d)	 if deemed receipt under the previous paragraphs of this clause 8.4 would occur outside business hours (meaning
9.00 am to 5.30 pm Monday to Friday on a day that is not a public holiday in the place of receipt), at 9.00 am on the day when business next starts in the place of receipt. For the purposes of this clause, all references to time are to local time in
the place of deemed receipt. 


  

	9.5	 This clause 8 does not apply to the service of any proceedings or other documents in any legal action or
proceedings or, where applicable, any arbitration or other method of dispute resolution. 


  

	10.	 SEVERANCE 



If any provision or part-provision of this agreement is or becomes invalid, illegal or unenforceable, it shall be deemed modified to the
minimum extent necessary to make it valid, legal and enforceable. If such modification is not possible, the relevant provision or part-provision shall be deemed deleted. Any modification to or deletion of a provision or part-provision under this
clause shall not affect the validity and enforceability of the rest of this agreement. 
  

	11.	 AGREEMENT SURVIVES THE DEMERGER EFFECTIVE DATE 



This agreement (other than obligations that have already been fully performed) remains in full force after the Demerger Effective Date. 

 

	12.	 THIRD PARTY RIGHTS 



 

	12.1	 This agreement does not give rise to any rights under the Contracts (Rights of Third Parties) Act 1999 to
enforce any term of this agreement. 



  
 6 














	12.2	 The rights of the parties to rescind or vary this agreement are not subject to the consent of any other person.



  

	13.	 COUNTERPARTS 



This agreement may be executed (either by wet-ink signature or by a party applying its signature by
some digital, electronic, mechanical or other means) in any number of counterparts, each of which shall constitute an original and all the counterparts shall together constitute one and the same agreement. The exchange of a fully executed (either by
wet-ink signature or by a party applying its signature by some digital, electronic, mechanical or other means) version of this agreement (in counterparts or otherwise) by electronic transmission in PDF format
or otherwise shall be sufficient to bind the parties to the terms and conditions of this agreement and no exchange of originals is necessary. 
  

	14.	 GOVERNING LAW AND JURISDICTION 



 

	14.1	 This agreement and any dispute or claim (including non-contractual
disputes or claims) arising out of or in connection with it or its subject matter or formation shall be governed by and construed in accordance with the laws of England and Wales. 



 

	14.2	 Each party irrevocably agrees that the courts of England and Wales shall have exclusive jurisdiction to settle
any dispute or claim (including non-contractual disputes or claims) that arises out of or in connection with this agreement or its subject matter or formation. 



This agreement has been entered into on the date stated at the beginning of it. 

  
 7 













 SCHEDULE 1 
  

			
	 Name
	  	 No. of Newco Shares

	Gabriele Cerrone	  	169,225
		
	Keeren Shah	  	5,000
		
	Hana Malik	  	5,000
		
	Tiziano Lazzaretti	  	150,000
		
	Dr Kunwar Shailubhai	  	400,000
		
	Vaseem Palejwala	  	20,000
		
	Jules Jacob	  	3,500
		
	Maria Preiss	  	3,000
		
	GarCer BioVentures	  	344,063


  
 8 














					
	 SIGNED by Gabriele Cerrone
 for
and on behalf of
 TIZIANA LIFE SCIENCES PLC
	  	 )
 )

)
	  	  
 /s/ Gabriele Cerrone

Director


  

					
	 SIGNED by Willy Jules Simon
 for
and on behalf of
 ACCUSTEM SCIENCES LIMITED
	  	 )
 )

)
	  	  
 /s/ Willy Jules Simon

Director



  
 9